Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Ameritas Advisory Services LLC

Posted by Defense World Staff on Jul 24th, 2023

Ameritas Advisory Services LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 8.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 268 shares of the biopharmaceutical company’s stock after selling 24 shares during the quarter. Ameritas Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $216,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Steward Financial Group LLC bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at approximately $28,000. Householder Group Estate & Retirement Specialist LLC increased its position in Regeneron Pharmaceuticals by 1,750.0% in the 1st quarter. Householder Group Estate & Retirement Specialist LLC now owns 37 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 35 shares during the period. Ridgewood Investments LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter worth approximately $46,000. Ritter Daniher Financial Advisory LLC DE bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $47,000. Finally, James Investment Research Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth approximately $58,000. Institutional investors and hedge funds own 89.21% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on REGN shares. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,050.00 to $1,045.00 in a report on Wednesday, June 28th. Bank of America boosted their target price on Regeneron Pharmaceuticals from $605.00 to $650.00 and gave the company an “underperform” rating in a research note on Wednesday, March 29th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 22nd. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,040.00 to $960.00 in a research report on Tuesday, July 18th. Finally, SVB Leerink upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday, March 27th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $868.25.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $735.42, for a total value of $73,542.00. Following the transaction, the director now owns 18,847 shares in the company, valued at approximately $13,860,460.74. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $735.42, for a total value of $73,542.00. Following the transaction, the director now owns 18,847 shares in the company, valued at approximately $13,860,460.74. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Marion Mccourt sold 250 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $710.09, for a total value of $177,522.50. Following the completion of the transaction, the executive vice president now owns 20,303 shares in the company, valued at approximately $14,416,957.27. The disclosure for this sale can be found here. Insiders sold 700 shares of company stock valued at $506,753 in the last three months. Corporate insiders own 8.83% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $734.63 on Monday. The stock has a market capitalization of $80.60 billion, a PE ratio of 19.96, a P/E/G ratio of 2.28 and a beta of 0.22. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.45 and a quick ratio of 4.67. The business has a fifty day moving average price of $739.48 and a two-hundred day moving average price of $758.30. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $563.82 and a fifty-two week high of $837.55.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last announced its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $8.44 earnings per share for the quarter, beating the consensus estimate of $7.71 by $0.73. The firm had revenue of $3.16 billion during the quarter, compared to analysts’ expectations of $2.92 billion. Regeneron Pharmaceuticals had a return on equity of 20.41% and a net margin of 33.81%. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 33.98 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.